Mobilisation of the European Globalisation Adjustment Fund: redundancies in the pharmaceutical sector in Sweden

Budgetary dossier on mobilising the European Globalisation Adjustment Fund for redundancies in the pharmaceutical sector in Sweden. Amendments note the application by the Swedish authorities and the Commission's assessment, the early start of measures, criticism of AstraZeneca increasing R&D investment in countries such as China and Russia, the highly skilled dismissed workers, participation incentives including job-search and mobility allowances, and a dedicated EGF allocation.